Mild Cognitive Impairment, Biomarker, Diagnosis, Treatment
Conditions
Brief summary
The purpose of this study is based on the Flutemetamol-PET senile plaque imaging to investigate the peripheral blood biochemical and brain MRI imaging biomarkers and to research completely independent intellectual property rights neuropsychological test tool for the MCI due to AD. At the same time, the investigators will study the efficacy and safety of early treatment of MCI due to AD by Huperzine A in 52 weeks.
Detailed description
This is a randmized, double-blind, placebo-controll study.
Interventions
DRUGHuperzine A
The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
DRUGPlacebo
The participants will treatment by the placebo in 52 weeks.
Sponsors
Shanghai Mental Health Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* memory complaint, preferably corroborated by a spouse or relative. * objective memory impairment. * normal general cognitive function. * intact activities of daily living. * absence of dementia. * the positive of brain senile plaque.
Exclusion criteria
* more than two lacuna ischemia (of diameter \< 1 cm) as revealed by MRI fluid-attenuated inversion recovery (FLAIR) sequence. * other type of dementia except AD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The average annual conversion rate in patients of MCI due to AD convert to the AD. | 52 weeks |
Countries
China
Contacts
Primary ContactTao Wang, M.D., Ph.D.
Outcome results
None listed